Full-Time

Strategic Delivery Lead

OpenAI

OpenAI

5,001-10,000 employees

Develops safe AI models and tools

Compensation Overview

$234k - $325k/yr

San Francisco, CA, USA

Hybrid

Hybrid role requiring 3 days on-site per week.

Category
Business & Strategy (2)
,
Required Skills
LLM
Requirements
  • Ten+ years leading multi-workstream technical programs.
  • Five+ years steering C-suite governance in a consulting role or a comparable leadership position in a technology company.
  • Ability to translate executive-level business outcomes into a delivery roadmap, milestones, dependencies, acceptance criteria, and value KPIs.
  • Experience leading cross-functional teams including engineers, researchers, product, and partnerships.
  • Ability to communicate with executives and articulate technical details with executive presence.
  • Technical fluency in core large language model solution patterns and integration fundamentals; ability to exercise technical judgment.
  • Willingness to spend 25-50% of time on-site with customers to unblock decisions and accelerate adoption.
  • Flexibility to travel 25-50%.
Responsibilities
  • Own strategic delivery for complex, multi-track programs as the single accountable directly responsible individual overseeing program success, translating business objectives into a roadmap with milestones, dependencies, acceptance criteria, and value KPIs.
  • Run day-to-day program execution by sequencing and unblocking work across Frontline Deployment Engineers, Researchers, Product, Partnerships, and customer teams; operate robust program management processes.
  • Protect the critical path by identifying delivery risks early and working cross-functionally to mitigate blockers and maintain program velocity.
  • Own executive communication and alignment by setting the narrative, running SteerCos and decision-ready readouts, surfacing risks early, and articulating technical details to executives.
  • Engage pre-close to de-risk delivery by co-leading discovery; shaping scope and commercials; designing the delivery plan and acceptance criteria; validating resourcing and risks.
  • Drive adoption and change management by embedding with customer stakeholders to map workflows, land production deployments, and ensure onboarding, training, and operating models support sustained use.
  • Codify patterns and playbooks by extracting reusable solution patterns and packaging field signals into pattern cards and product requests to shorten time-to-value on future deployments.
  • Own value cases and ROI by setting impact hypotheses, baselines, and KPIs; conducting pre- and post-measurement; reporting outcomes to executive sponsors and aligning on expansion.

OpenAI conducts AI research and deployment to build advanced AI models and tools that help people automate tasks, be more creative, and make better decisions. Its products include ChatGPT, a conversational AI that can write, code, tutor, and assist in interactive tasks, and Sora, which can generate videos from text prompts. OpenAI’s models typically run through cloud-based services and subscriptions, with licensing and partnerships for broader use. The company operates a capped-profit model to balance generating revenue with ensuring safety, ethics, and long-term societal benefits. Its approach emphasizes safety, responsible deployment, and collaboration with researchers, governments, and institutions. The goal is to ensure artificial general intelligence, when it arrives, benefits all of humanity and minimizes risks.

Company Size

5,001-10,000

Company Stage

Late Stage VC

Total Funding

$196B

Headquarters

San Francisco, California

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • SoftBank pledges $30B more in 2026, valuing OpenAI at $850B with $25B annualized revenue.
  • University of Michigan's $20M investment yields $2B, signaling strong early investor returns.
  • TPG joint venture with billions in PE funding boosts corporate AI adoption rates.

What critics are saying

  • Microsoft divests after $100B spend by June 2026, funding Anthropic and xAI instead.
  • Doubled GPT-5.5 API prices to $5/$30 per million tokens slash 5% subscriber conversions.
  • Europe bans GPT-5.5-Cyber for non-partners post-Mythos, blocking Trusted Access expansion.

What makes OpenAI unique

  • Trusted Access for Cyber grants vetted users GPT-5.4-Cyber for binary reverse engineering.
  • Daybreak platform automates threat prioritization, patching, and fix verification in software development.
  • Deployment Company with 150 Tomoro engineers accelerates enterprise AI integration via partnerships.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at OpenAI who can refer or advise you

Benefits

Health insurance

Dental and vision insurance

Flexible spending account for healthcare and dependent care

Mental healthcare service

Fertility treatment coverage

401(k) with generous matching

20-week paid parental leave

Life insurance (complimentary)

AD&D insurance (complimentary)

Short-term/long-term disability insurance (complimentary)

Optional buy-up life insurance

Flexible work hours and unlimited paid time off (we encourage 4+ weeks per year)

Annual learning & development stipend

Regular team happy hours and outings

Daily catered lunch and dinner

Travel to domestic conferences

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

3%

2 year growth

2%
Daring Fireball
May 8th, 2026
Y Combinator’s Stake in OpenAI

The fact that Paul Graham personally has billions of dollars at stake with OpenAI doesn’t mean that his public opinion on Sam Altman’s trustworthiness and leadership is invalid. But it certainly seems like the sort of thing that ought to be disclosed when quoting Graham as an Altman character reference.

Bloomberg L.P.
Apr 21st, 2026
OpenAI launches ChatGPT Images 2.0 with improved chart and diagram creation

OpenAI is releasing ChatGPT Images 2.0, an updated AI image-generating software designed to create accurate charts and scientific diagrams. The company aims to make its technology more appealing to professionals. Rolling out Tuesday through ChatGPT and Codex AI coding assistant, the new model improves instruction-following and detail incorporation when generating images. It can produce visuals across multiple styles and render text in various languages. The update represents OpenAI's effort to expand its AI capabilities beyond general use cases into professional applications requiring technical precision and accuracy.

Bloomberg L.P.
Apr 17th, 2026
OpenAI loses head of science initiatives and Sora AI video team leader

OpenAI's head of science initiatives and the leader of its Sora AI video team are leaving the company, adding to recent executive departures as the firm reorganises its product portfolio. The exits continue a pattern of senior leadership changes at the artificial intelligence company.

Bloomberg L.P.
Apr 16th, 2026
OpenAI unveils GPT-5.4 to tackle enterprise trust and governance concerns

OpenAI is addressing enterprise adoption challenges with GPT-5.4 "Cyber", focusing on security, trust and governance issues. Erica Brescia, managing director at Redpoint Ventures and OpenAI backer, discussed the development, emphasising that the AI cyber race centres on governance rather than purely technological advancement. The move represents OpenAI's effort to overcome barriers preventing widespread enterprise adoption of its AI systems by prioritising security features in its latest model release.

Bloomberg L.P.
Apr 16th, 2026
OpenAI launches GPT-Rosalind AI model for drug discovery to rival Google

OpenAI has launched GPT-Rosalind, an AI model designed to accelerate drug discovery and life sciences research. The model aims to extract insights from large datasets and help translate scientific studies into healthcare applications. Initially available as a research preview to select business customers, GPT-Rosalind's early users include pharmaceutical company Amgen, vaccine maker Moderna and bioscience research nonprofit the Allen Institute. The launch positions OpenAI alongside other technology companies entering the drug discovery field, as the industry seeks to demonstrate AI's potential for scientific breakthroughs. The ChatGPT maker announced the model's release on Thursday.